Regulus Therapeutics reported $-7321000 in EBITDA for its fiscal quarter ending in March of 2023.

Ebitda Change Date
AstraZeneca USD 3.43B 412M Sep/2023
Clal Biotechnology ILS -5295000 2.09M Dec/2022
CSL USD 1.38B 1.22B Jun/2023
Gilead Sciences USD 2.73B 579M Dec/2023